111 related articles for article (PubMed ID: 20659591)
1. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
2. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
5. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells.
Sharabi A; Mozes E
J Immunol; 2008 Sep; 181(5):3243-51. PubMed ID: 18713995
[TBL] [Abstract][Full Text] [Related]
6. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
Mauermann N; Sthoeger Z; Zinger H; Mozes E
Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
[TBL] [Abstract][Full Text] [Related]
9. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice.
Sharabi A; Sthoeger ZM; Mahlab K; Lapter S; Zinger H; Mozes E
Clin Immunol; 2009 Oct; 133(1):61-8. PubMed ID: 19631585
[TBL] [Abstract][Full Text] [Related]
10. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
[TBL] [Abstract][Full Text] [Related]
11. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
[TBL] [Abstract][Full Text] [Related]
13. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
14. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
[TBL] [Abstract][Full Text] [Related]
15. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
[TBL] [Abstract][Full Text] [Related]
16. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
Sharabi A; Dayan M; Zinger H; Mozes E
J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
[TBL] [Abstract][Full Text] [Related]
17. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
Ben-David H; Sharabi A; Parameswaran R; Zinger H; Mozes E
Immunology; 2009 Oct; 128(2):245-52. PubMed ID: 19740381
[TBL] [Abstract][Full Text] [Related]
18. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
19. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
